Corcept Therapeutics Incorporated Common Stock (CORT) fair value

ACCE thesis

Corcept sells Korlym (mifepristone) for hypercortisolism and is building out relacorilant, a cortisol receptor modulator it is developing for Cushing's syndrome and platinum-resistant ovarian cancer. The business is almost entirely a single-franchise story, which makes its moat a function of patent life and regulatory exclusivity rather than scale or switching costs. Revenue growth of 31.7% and a 98.3% gross margin show how much of each sales dollar drops through, though the 16.1% operating margin says a good share is going back into the pipeline and sales force. Trailing earnings are thin at a 263.7 P/E, but the 19.3 forward P/E implies the market is pricing a sharp step-up in profitability, so the relacorilant readouts and launch timing are the items to pin down before anything else. Return on equity of 8.2% is modest for a business with this margin structure, which is worth understanding on the balance sheet side. The name merits a deeper look if the team can confirm the durability of Korlym exclusivity and the probability-weighted value of the pipeline.